RESUMO
Infections with arboviruses are reported worldwide. Saint Louis encephalitis (SLEV) and West Nile (WNV) viruses are closely related flaviviruses affecting humans and animals. SLEV has been sporadically detected in humans, and corresponding antibodies have been frequently detected in horses throughout Brazil. WNV was first reported in western Brazil over a decade ago, has been associated with neurological disorders in humans and equines and its prevalence is increasing nationwide. Herein, we investigated by molecular and serological methods the presence of SLEV and WNV in equines from Rio de Janeiro. A total of 435 serum samples were collected from healthy horses and tested for specific neutralizing antibodies by plaque reduction neutralization test (PRNT90). Additionally, samples (serum, cerebrospinal fluid, central nervous system tissue) from 72 horses, including horses with neurological disorders resulting in a fatal outcome or horses which had contact with them, were tested by real-time reverse transcription-polymerase chain reaction (RT-qPCR) for both viruses. Adopting the criterion of four-fold antibody titer difference, 165 horses (38%) presented neutralizing antibodies for flaviviruses, 89 (20.4%) for SLEV and five (1.1%) for WNV. No evidence of SLEV and WNV infection was detected by RT-qPCR and, thus, such infection could not be confirmed in the additional samples. Our findings indicate horses of Rio de Janeiro were exposed to SLEV and WNV, contributing to the current knowledge on the distribution of these viruses in Brazil.
Assuntos
Encefalite de St. Louis , Flavivirus , Doenças dos Cavalos , Febre do Nilo Ocidental , Vírus do Nilo Ocidental , Animais , Humanos , Cavalos , Vírus do Nilo Ocidental/genética , Encefalite de St. Louis/epidemiologia , Encefalite de St. Louis/veterinária , Brasil/epidemiologia , Anticorpos Antivirais , Febre do Nilo Ocidental/epidemiologia , Febre do Nilo Ocidental/veterinária , Anticorpos Neutralizantes , Doenças dos Cavalos/epidemiologiaRESUMO
The genus Orthopoxvirus (OPXV) of the family Poxviridae comprises several viruses that are capable of infecting a wide range of hosts. One of the most widespread OPXVs is the Vaccinia virus (VACV), which circulates in zoonotic cycles in South America, especially in Brazil, infecting domestic and wild animals and humans and causing economic losses as well as impacting public health. Despite this, little is known about the presence and/or exposure of neotropical primates to orthopoxviruses in the country. In this study, we report the results of a search for evidence of OPVX infections in neotropical free-living primates in the state of Minas Gerais, southeast Brazil. The sera or liver tissues of 63 neotropical primates were examined through plaque reduction neutralization tests (PRNT) and real-time PCR. OPXV-specific neutralizing antibodies were detected in two sera (4.5%) from Callithrix penicillata, showing 55% and 85% reduction in plaque counts, evidencing their previous exposure to the virus. Both individuals were collected in urban areas. All real-time PCR assays were negative. This is the first time that evidence of OPXV exposure has been detected in C. penicillata, a species that usually lives at the interface between cities and forests, increasing risks of zoonotic transmissions through spillover/spillback events. In this way, studies on the circulation of OPXV in neotropical free-living primates are necessary, especially now, with the monkeypox virus being detected in new regions of the planet.
RESUMO
Accurate diagnostics underpin effective public health responses to emerging viruses. For viruses, such as Zika virus (ZIKV), where the viremia clears quickly, antibody-based (IgM or IgG) diagnostics are recommended for patients who present 7 days after symptom onset. However, cross-reactive antibody responses can complicate test interpretation among populations where closely related viruses circulate. We examined the accuracy (proportion of samples correctly categorized as Zika positive or negative) for antibody-based diagnostics among Brazilian residents (Rio de Janeiro) during the ZIKV outbreak. Four ZIKV enzyme-linked immunosorbent assays (ELISAs; IgM and IgG Euroimmun, IgM Novagnost, and CDC MAC), two dengue ELISAs (IgM and IgG Panbio), and the ZIKV plaque reduction neutralization test (PRNT) were evaluated. Positive samples were ZIKV PCR confirmed clinical cases collected in 2015-2016 (n = 169); negative samples (n = 236) were collected before ZIKV was present in Brazil (≤2013). Among serum samples collected ≥7 days from symptom onset, PRNT exhibited the highest accuracy (93.7%), followed by the Euroimmun IgG ELISA (77.9%). All IgM assays exhibited lower accuracy (<75%). IgG was detected more consistently than IgM among ZIKV cases using Euroimmun ELISAs (68% versus 22%). Anti-dengue virus IgM ELISA was positive in 41.1% of confirmed ZIKV samples tested. The Euroimmun IgG assay, although misdiagnosing 22% of samples, provided the most accurate ELISA. Anti-ZIKV IgG was detected more reliably than IgM among ZIKV patients, suggesting a secondary antibody response to assay antigens following ZIKV infection. Antibody ELISAs need careful evaluation in their target population to optimize use and minimize misdiagnosis, prior to widespread deployment, particularly where related viruses cocirculate.
Assuntos
Infecção por Zika virus , Zika virus , Anticorpos Antivirais , Brasil , Ensaio de Imunoadsorção Enzimática , Humanos , Imunoglobulina G , Imunoglobulina M , Testes Sorológicos , Infecção por Zika virus/diagnósticoRESUMO
Zika virus (ZIKV) was first discovered in 1947 in Uganda but was not considered a public health threat until 2007 when it found to be the source of epidemic activity in Asia. Epidemic activity spread to Brazil in 2014 and continued to spread throughout the tropical and subtropical regions of the Americas. Despite ZIKV being zoonotic in origin, information about transmission, or even exposure of non-human vertebrates and mosquitoes to ZIKV in the Americas, is lacking. Accordingly, from February 2017 to March 2018, we sought evidence of sylvatic ZIKV transmission by sampling whole blood from approximately 2000 domestic and wild vertebrates of over 100 species in West-Central Brazil within the active human ZIKV transmission area. In addition, we collected over 24,300 mosquitoes of at least 17 genera and 62 species. We screened whole blood samples and mosquito pools for ZIKV RNA using pan-flavivirus primers in a real-time reverse-transcription polymerase chain reaction (RT-PCR) in a SYBR Green platform. Positives were confirmed using ZIKV-specific envelope gene real-time RT-PCR and nucleotide sequencing. Of the 2068 vertebrates tested, none were ZIKV positive. Of the 23,315 non-engorged mosquitoes consolidated into 1503 pools tested, 22 (1.5%) with full data available showed some degree of homology to insect-specific flaviviruses. To identify previous exposure to ZIKV, 1498 plasma samples representing 62 species of domestic and sylvatic vertebrates were tested for ZIKV-neutralizing antibodies by plaque reduction neutralization test (PRNT90). From these, 23 (1.5%) of seven species were seropositive for ZIKV and negative for dengue virus serotype 2, yellow fever virus, and West Nile virus, suggesting potential monotypic reaction for ZIKV. Results presented here suggest no active transmission of ZIKV in non-human vertebrate populations or in alternative vector candidates, but suggest that vertebrates around human populations have indeed been exposed to ZIKV in West-Central Brazil.
Assuntos
Infecção por Zika virus/epidemiologia , Infecção por Zika virus/virologia , Zika virus , Animais , Brasil/epidemiologia , Culicidae , Geografia Médica , Humanos , Mosquitos Vetores , Testes de Neutralização , Vigilância em Saúde Pública , Estudos Soroepidemiológicos , Infecção por Zika virus/transmissão , ZoonosesRESUMO
In the Americas, hantaviruses cause severe cardiopulmonary syndrome (HCPS) with a high fatality rate. Hantavirus infection is commonly diagnosed using serologic techniques and reverse transcription-polymerase chain reaction. This paper presents a novel plaque reduction neutralisation test (PRNT) for detecting antibodies to Brazilian hantavirus. Using PRNT, plaque detection was enhanced by adding 0.6% of dimethyl sulfoxide into the overlay culture medium of the infected cells. This procedure facilitated clear visualisation of small plaques under the microscope and provided for easy and accurate plaque counting. The sera from 37 HCPS patients from the city of Ribeirão Preto, Brazil was evaluated for the Rio Mamoré virus (RIOMV) using PRNT. Six samples exhibited neutralising antibodies; these antibodies exhibited a low titre. The low level of seropositive samples may be due to fewer cross-reactions between two different hantavirus species; the patients were likely infected by Araraquara virus (a virus that has not been isolated) and RIOMV was used for the test. This assay offers a new approach to evaluating and measuring neutralising antibodies produced during hantavirus infections and it can be adapted to other hantaviruses, including viruses that will be isolated in the future.
.Assuntos
Humanos , Anticorpos Antivirais/sangue , Síndrome Pulmonar por Hantavirus/diagnóstico , Testes de Neutralização/métodos , Anticorpos Antivirais/imunologia , Ensaio de Imunoadsorção Enzimática , Síndrome Pulmonar por Hantavirus/virologia , Orthohantavírus/crescimento & desenvolvimento , Orthohantavírus/imunologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Sensibilidade e Especificidade , Ensaio de Placa ViralRESUMO
Measles virus (MeV) represents one of the main causes of death among young children, particularly in developing countries. Upon infection, MeV controls both interferon induction (IFN) and the interferon signaling pathway which results in a severe host immunosuppression that can persists for up to 6 mo after infection. Despite the global biology of MeV infection is well studied, the role of the plasmacytoid dendritic cells (pDCs) during the host innate immune response after measles vaccination remains largely uncharacterized. Here we investigated the role of pDCs, the major producers of interferon in response to viral infections, in the development of adaptive immune response against MeV vaccine. We report that there is a strong correlation between pDCs population and the humoral immune response to Edmonston Zagreb (EZ) measles vaccination in 9-month-old mexican infants. Five infants were further evaluated after vaccination, showing a clear increase in pDCs at baseline, one week and 3 months after immunization. Three months postvaccination they showed increase in memory T-cells and pDCs populations, high induction of adaptive immunity and also observed a correlation between pDCs number and the humoral immune response. These findings suggest that the development and magnitude of the adaptive immune response following measles immunization is directly dependent on the number of pDCs of the innate immune response.
Assuntos
Anticorpos Antivirais/análise , Células Dendríticas/imunologia , Vacina contra Sarampo/imunologia , Sarampo/imunologia , Imunidade Adaptativa/imunologia , Adulto , Fatores Etários , Anticorpos Neutralizantes/análise , Contagem de Células , Feminino , Humanos , Imunidade Humoral/imunologia , Imunidade Inata/imunologia , Lactente , Masculino , Vacina contra Sarampo/efeitos adversos , México , Linfócitos T/imunologia , Vacinação , Ensaio de Placa ViralRESUMO
UNLABELLED: Several ChimeriVax-Dengue (CYD)-based vaccination strategies were investigated as potential alternatives to vaccination with tetravalent CYD vaccine (CYD-TDV) in this phase IIa trial conducted in 2008-9 in 150 healthy adults. Participants were randomized and vaccinated on D0 and D105 (± 15 days). One group received bivalent CYD vaccine against serotypes 1 and 3 (CYD-1;3) on day 0 and CYD-2;4 on day 105 (± 15 days). Two groups received an injection at each timepoint of a tetravalent blend of CYD-1;3;4 and a VERO cell derived, live attenuated vaccine against serotype 2 (VDV-2), or the reference CYD-TDV. A fourth group received Japanese encephalitis (JE) vaccine on days -14, -7 and 0, followed by CYD-TDV on day 105. Viraemia was infrequent in all groups. CYD-4 viraemia was most frequent after tetravalent vaccination, while CYD-3 viraemia was most frequent after the first bivalent vaccination. Immunogenicity as assessed by 50% plaque reduction neutralisation test on D28 was comparable after the first injection of either tetravalent vaccine, and increased after the second injection, particularly with the blended CYD-1;3;4/ VDV-2 vaccine. In the bivalent vaccine group, immune response against serotype 3 was highest and the second injection elicited a low immune response against CYD 2 and 4. Immune responses after the first injection of CYD-TDV in the JE-primed group were in general higher than after the first injection in the other groups. All tested regimens were well tolerated without marked differences between groups. Bivalent vaccination showed no advantage in terms of immunogenicity. CLINICAL TRIAL REGISTRATION NUMBER: NCT00740155.
Assuntos
Anticorpos Antivirais/sangue , Vacinas contra Dengue/imunologia , Vírus da Dengue/imunologia , Dengue/imunologia , Viremia/sangue , Adolescente , Adulto , Anticorpos Neutralizantes/sangue , Anticorpos Neutralizantes/imunologia , Anticorpos Antivirais/imunologia , Dengue/prevenção & controle , Vacinas contra Dengue/efeitos adversos , Vacinas contra Dengue/uso terapêutico , Feminino , Humanos , Imunidade Celular/imunologia , Imunidade Humoral/imunologia , Vacinas contra Encefalite Japonesa/efeitos adversos , Vacinas contra Encefalite Japonesa/imunologia , Vacinas contra Encefalite Japonesa/uso terapêutico , Masculino , México , Testes de Neutralização , Vacinação , Vacinas Atenuadas/efeitos adversos , Vacinas Atenuadas/imunologia , Vacinas Atenuadas/uso terapêutico , Viremia/imunologia , Vacinas contra o Vírus do Nilo Ocidental/efeitos adversos , Vacinas contra o Vírus do Nilo Ocidental/imunologia , Vacinas contra o Vírus do Nilo Ocidental/uso terapêutico , Adulto JovemRESUMO
OBJETIVO: Analizar la distribución y frecuencia de anticuerpos protectores contra sarampión en una muestra representativa estatal en niños de 1-9 años, así como contribuir a la evaluación de los programas de vacunación contra este agente. MATERIAL Y MÉTODOS: Se estudió la presencia de anticuerpos contra el virus del sarampión en una muestra de la Encuesta Nacional de Salud 2000. Los sueros se recolectaron de noviembre de 1999 a junio de 2000. La muestra consta de 6 270 niños y se utilizó la técnica de reducción de placas por neutralización. RESULTADOS: La seropositividad (>120 UI/L) de los niños de 1-4 años fue menor que la de los niños de 5-9 años, 98.3 por ciento (IC95 por ciento 97.7-98.8) contra 99.4 por ciento (IC95 por ciento 99.2-99.6, p<0.001). Los niveles de seropositividad se incrementaron con el número de dosis de vacuna de sarampión o sarampión-rubeola-parotiditis y no dependen de género, residencia o nivel socioeconómico. CONCLUSIONES: Los resultados muestran que existe una cobertura adecuada en la vacunación; sin embargo, al expandir los datos se observó que existen 417 000 niños que presentaron títulos negativos de anticuerpos, por lo que son susceptibles de adquirir, transmitir el virus y contribuir a la generación de brotes de la enfermedad.
OBJECTIVE: To analyze the frequency and distribution of protective antibodies against measles in a sample of children from 1-9 years old representative of each of the 32 states in Mexico; to contribute to the evaluation of the measles vaccination programs. MATERIAL AND METHODS: Measles antibodies (plaque reduction neutralization (PRN) assay) were studied in 6 270 sera selected from the 24 232 sera from children 1-9 years of age, collected by the 2000 National Health Survey (ENSA 2000) that was conducted from November 1999 to June 2000. RESULTS: Proportion of seropositive samples (>120 IU/L) among 1-4 year-old children (98.3 percent [95 percentCI: 97.7-98.8]) was less than that of 5-9 year-old children (99.4 percent [95 percentCI: 99.2-99.6]; p<0.001). Seropositivity was associated with the number of measles and/or measles-rubella-mumps vaccine doses and was not associated with gender, place of residence or socio-economic status. CONCLUSIONS: The results show that there is adequate vaccination coverage. However, the expansion of data revealed that there are 417 000 children with negative antibody titers who are susceptible to acquiring the disease, transmitting the virus and causing outbreaks.